推荐产品
等级
pharmaceutical primary standard
API类
sorafenib
制造商/商品名称
EDQM
应用
pharmaceutical
格式
neat
储存温度
2-8°C
InChI
1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
InChI key
MLDQJTXFUGDVEO-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
本品按现行药典规定交付。该产品的所有支持信息，包括SDS和任何产品信息宣传页均由药典发行机构制定并发布。如需更多信息和支持，请见现行药典的网站。
应用
索拉非尼（EP参考标准品）仅用于欧洲药典中明确规定的实验室测试用途。
包装
本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。
其他说明
可能适用相应的销售限制。
相关产品
产品编号
说明
价格
警示用语：
Danger
危险分类
Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Ye Kuang et al.
Cancer medicine, 12(6), 7222-7233 (2022-11-25)
Hepatocellular carcinoma (HCC) is a primary liver cancer with high mortality. The long-term use of sorafenib, a targeted drug for hepatocellular carcinoma, will lead to drug resistance, and patients are prone to cancer metastasis, the molecular mechanism of which is
Zhong Wan et al.
Aging, 12(18), 18192-18208 (2020-10-07)
We investigated MAPK14-dependent resistance to sorafenib in hepatocellular carcinoma (HCC). Bioinformatics analysis and dual luciferase reporter assays in HCC cell lines showed that miR-216a-3p directly binds to the 3'UTR of MAPK14 mRNA and downregulates MAPK14 protein expression. Consequently, miR-216a-3p expression
Su-Hong Chen et al.
Experimental and therapeutic medicine, 23(3), 232-232 (2022-03-01)
Sorafenib is currently used to treat hepatocellular carcinoma (HCC). However, the development of chemoresistance to sorafenib is a major limitation for sorafenib-based therapy in patients with HCC. In the present study, the effect of the combination therapy of sorafenib and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门